MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Combined Plantar Stimulations Using a Novel Parkinson Shoe benefit Parkinson’s Disease Patients with Unresponsive Freezing of Gait

    W. Phuenpathom, P. Panyakaew, S. Fungtammasan, P. Vateekul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To explore the effect of combined vibratory and pressure stimulations in PD patients with unresponsive FOG and develop the innovative PD shoe. Background: Freezing…
  • MDS Virtual Congress 2021

    Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre

    A. Redmond, G. Richard, M. Penugonda, D. Bradley (Dublin 8, Ireland)

    Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…
  • MDS Virtual Congress 2021

    Opicapone in clinical practice in Parkinson’s disease patients with motor fluctuations and complications of therapy at baseline: findings from the OPTIPARK study

    H. Reichmann, A. Lees, M. Fonseca, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: This post-hoc analysis evaluated the effects of opicapone (OPC) treatment in patients with Parkinson’s disease (PD) who experience motor fluctuations and complications of therapy…
  • MDS Virtual Congress 2021

    Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

    H. Reichmann, T. Warnecke, A. Lees, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of monoamine-oxidase-B…
  • MDS Virtual Congress 2021

    Opicapone in Parkinson’s Disease German Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    H. Reichmann, A. Lees, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: To evaluate opicapone (OPC) when used in everyday clinical practice conditions to treat Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC proved to…
  • MDS Virtual Congress 2021

    Evaluation of a double-target therapeutic in preclinical models of Parkinson’s disease

    FJ. Sanz, C. Solana-Manrique, E. Masià, MJ. Vicent, N. Paricio (Burjassot, Spain)

    Objective: To evaluate the effectiveness of a candidate compound identified in a high-throughput screening (HTS) assay carried out in a Drosophila model of Parkinson’s disease…
  • MDS Virtual Congress 2021

    Causes of deaths in patients with Parkinson’s disease in the era before the use of modern drug therapy and at the present time

    S. Shtaimets (Omsk, Russian Federation)

    Objective: to study the impact of modern pharmacotherapy of Parkinson's disease (PD) on the main causes of death. Background: the modern era of the use…
  • MDS Virtual Congress 2021

    Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study problems faced by PD patients during lockdown due lack of healthcare and medication procurement and address such problems using telemedicine via virtual…
  • MDS Virtual Congress 2021

    Beta-antagonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

    A. Singh, S. Hussain, B. Antony (Hobart, Australia)

    Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of β-antagonist and the risk of PD.…
  • MDS Virtual Congress 2021

    Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension

    M. Soileau, I. Malaty, J. Aldred, A. Merola, R. Rodriguez, N. Gupta, I. Sultan, P. Kandukuri, Y. Jalundhwala, O. Ladhani, I. Pan, R. Pahwa (Georgetown, USA)

    Objective: To describe the real-world characteristics of advanced Parkinson’s disease (APD) patients initiating carbidopa/levodopa enteral suspension (CLES) therapy in USA Background: CLES is an FDA…
  • « Previous Page
  • 1
  • …
  • 953
  • 954
  • 955
  • 956
  • 957
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley